CA3101514A1 - Regimens and methods of treating multiple sclerosis using ofatumumab - Google Patents

Regimens and methods of treating multiple sclerosis using ofatumumab

Info

Publication number
CA3101514A1
CA3101514A1 CA3101514A CA3101514A CA3101514A1 CA 3101514 A1 CA3101514 A1 CA 3101514A1 CA 3101514 A CA3101514 A CA 3101514A CA 3101514 A CA3101514 A CA 3101514A CA 3101514 A1 CA3101514 A1 CA 3101514A1
Authority
CA
Canada
Prior art keywords
ofatumumab
regimen
dose
during
maintenance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3101514A
Other languages
English (en)
French (fr)
Inventor
Erik Wallstrom
Marina SAVELIEVA PRAZ
Algirdas Jonas KAKARIEKA WEISSKOPF
Joseph Michael KAHN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3101514A1 publication Critical patent/CA3101514A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3101514A 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab Pending CA3101514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15
US62/374,986 2016-08-15
CA3030530A CA3030530C (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3030530A Division CA3030530C (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Publications (1)

Publication Number Publication Date
CA3101514A1 true CA3101514A1 (en) 2018-02-22

Family

ID=59901554

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3101514A Pending CA3101514A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab
CA3030530A Active CA3030530C (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3030530A Active CA3030530C (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Country Status (24)

Country Link
US (5) US11161909B2 (enExample)
EP (5) EP4252847A3 (enExample)
JP (2) JP6851391B2 (enExample)
KR (2) KR20200136503A (enExample)
CN (5) CN120053639A (enExample)
AU (2) AU2017311664C1 (enExample)
CA (2) CA3101514A1 (enExample)
CY (1) CY1123350T1 (enExample)
DE (1) DE202017007542U1 (enExample)
DK (2) DK3733712T3 (enExample)
ES (2) ES2954259T3 (enExample)
FI (1) FI3733712T3 (enExample)
HR (2) HRP20230894T1 (enExample)
HU (2) HUE051948T2 (enExample)
IL (4) IL276890B2 (enExample)
LT (2) LT3497132T (enExample)
MX (1) MX388593B (enExample)
PL (2) PL3497132T3 (enExample)
PT (2) PT3497132T (enExample)
RS (2) RS64541B1 (enExample)
RU (1) RU2749951C2 (enExample)
SI (2) SI3497132T1 (enExample)
TW (1) TWI752995B (enExample)
WO (1) WO2018033841A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4252847A3 (en) 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
JP7794735B2 (ja) 2019-09-11 2026-01-06 ノバルティス アーゲー 切替え療法によるｒｍｓの治療
WO2021204994A1 (en) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg
CN117529336A (zh) * 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗
WO2026099463A1 (en) 2024-11-08 2026-05-15 Novartis Ag Glycoengineered anti-cd20 antibodies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
MXPA02009523A (es) 2000-03-30 2003-02-12 Amgen Inc Moleculas similares a cd20/receptor de ige y usos de las mismas.
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
AR082436A1 (es) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc Uso de teriflunomida para tratar la esclerosis multiple
EP2663331A4 (en) * 2011-01-10 2015-07-15 Glaxosmithkline Intellectual Property Man Ltd NEW USES
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
CN104603124B (zh) 2012-08-10 2018-04-17 勃林格殷格翰国际有限公司 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
EP3250927B1 (en) * 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN106699886A (zh) 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
EP4252847A3 (en) 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab
US20220389109A1 (en) 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
JP7794735B2 (ja) 2019-09-11 2026-01-06 ノバルティス アーゲー 切替え療法によるｒｍｓの治療
WO2021204994A1 (en) 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg
CN117529336A (zh) 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗
JP2024531314A (ja) 2021-08-16 2024-08-29 ノバルティス アーゲー 小児ｍｓを治療するためのオファツムマブ

Also Published As

Publication number Publication date
TWI752995B (zh) 2022-01-21
AU2017311664A1 (en) 2019-01-31
IL276890B1 (en) 2023-06-01
MX388593B (es) 2025-03-20
WO2018033841A1 (en) 2018-02-22
KR20200136503A (ko) 2020-12-07
ES2821924T3 (es) 2021-04-28
FI3733712T3 (fi) 2023-08-22
AU2017311664C1 (en) 2025-05-22
EP4252847A2 (en) 2023-10-04
US11161909B2 (en) 2021-11-02
CN109641965A (zh) 2019-04-16
AU2020201112C1 (en) 2025-05-22
EP4252847A3 (en) 2023-11-15
US20240150485A1 (en) 2024-05-09
HUE063625T2 (hu) 2024-01-28
DK3733712T3 (da) 2023-08-21
ES2954259T3 (es) 2023-11-21
EP4711008A2 (en) 2026-03-18
IL302488B1 (en) 2024-08-01
HRP20230894T1 (hr) 2023-11-24
IL276890A (en) 2020-10-29
RS60807B1 (sr) 2020-10-30
US12338290B2 (en) 2025-06-24
KR20190038914A (ko) 2019-04-09
CN120000782A (zh) 2025-05-16
LT3497132T (lt) 2020-10-12
US20190177424A1 (en) 2019-06-13
EP4711008A3 (en) 2026-06-03
US20250289902A1 (en) 2025-09-18
TW201808333A (zh) 2018-03-16
RU2019107146A (ru) 2020-09-15
CN120053638A (zh) 2025-05-30
IL313932A (en) 2024-08-01
DK3497132T3 (da) 2020-09-07
AU2020201112B2 (en) 2021-07-22
LT3733712T (lt) 2023-09-11
RU2021105514A3 (enExample) 2022-02-08
DE202017007542U1 (de) 2022-07-19
HUE051948T2 (hu) 2021-03-29
CN120037367A (zh) 2025-05-27
EP3733712B1 (en) 2023-05-24
US20220081488A1 (en) 2022-03-17
PL3733712T3 (pl) 2023-10-16
AU2020201112A1 (en) 2020-03-05
EP4371611A3 (en) 2024-07-24
PT3733712T (pt) 2023-08-31
MX2019001860A (es) 2019-07-08
AU2017311664B2 (en) 2020-01-02
US20240317878A1 (en) 2024-09-26
RU2019107146A3 (enExample) 2020-09-15
SI3497132T1 (sl) 2020-10-30
CA3030530A1 (en) 2018-02-22
CY1123350T1 (el) 2021-12-31
JP2020100630A (ja) 2020-07-02
CA3030530C (en) 2021-02-23
IL302488A (en) 2023-06-01
HRP20201388T1 (hr) 2020-11-27
PT3497132T (pt) 2020-09-25
SI3733712T1 (sl) 2023-12-29
PL3497132T3 (pl) 2020-11-30
IL264804B (en) 2020-09-30
IL276890B2 (en) 2023-10-01
EP3497132B1 (en) 2020-06-24
RU2021105514A (ru) 2021-04-19
EP4371611B1 (en) 2026-06-17
JP6851391B2 (ja) 2021-03-31
EP3497132A1 (en) 2019-06-19
IL302488B2 (en) 2024-12-01
CN120053639A (zh) 2025-05-30
RS64541B1 (sr) 2023-09-29
JP7198786B2 (ja) 2023-01-04
JP2019511506A (ja) 2019-04-25
EP4371611A2 (en) 2024-05-22
RU2749951C2 (ru) 2021-06-21
EP3733712A1 (en) 2020-11-04
US12570754B2 (en) 2026-03-10

Similar Documents

Publication Publication Date Title
US12570754B2 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40101642A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40111448A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
RU2782069C2 (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
HK40032047A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40032047B (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40005527A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40005527B (en) Regimens and methods of treating multiple sclerosis using ofatumumab

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220601

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240726

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241205

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D138 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW PERFORMED

Effective date: 20250218

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D136 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST AUTHORIZED

Effective date: 20250218

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D135 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST RECEIVED

Effective date: 20250218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250415

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250702

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250702

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250722

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250829

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250829

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250909

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250909

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D16-D106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20250919

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20250925

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250925

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251216

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260416

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260428

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260525

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260525

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260630

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260721

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260721